references
1. Health care provider recommendation, human papilloma-
virus vaccination, and race/ethnicity in the U.S. National
Immunization Survey. American Journal of Public Health.
2013. 103(1):164–169.2012. 30(20):3112–3118.
2. Factors associated with human papillomavirus vaccine-
series initiation and healthcare provider recommendation
in U.S. adolescent females: 2007 National Survey of Chil-
dren’s Health. Vaccine. 2012. 30(20):3112–3118.
3. Genital HPV Infection – CDC Fact Sheet. Available at:
www.cdc.gov/std/hpv/HPV-FS-print.pdf.
4. HPV-associated cancer statistics. Available at: www.cdc.
gov/cancer/hpv/statistics.
5. National, Regional, State, and Selected Local Area Vacci-
nation Coverage Among Adolescents Aged 13–17 Years –
United States, 2019. MMWR. 2020. 69(33);1109–1116.
6. Safety update of HPV vaccines. Available at: www.who.
int/vaccine_safety/committee/topics/hpv/June_2017/en.
7.HPVvaccinesafetyandeectivenessdata.Availableat:
www.cdc.gov/hpv/hcp/vaccine-safety-data.html.
8. Reasons for lack of HPV vaccine initiation in NIS-Teen
over time: shifting the focus from gender and sexuality
to necessity and safety. Journal of Adolescent Health.
2018. 63(5):652–656
•
More than 13 years of post-licensure vaccine safety monitoring in the United States provides continued evi-
dence of the safety of HPV vaccines. Data on safety are also available from post-licensure monitoring in other
countries and provide continued evidence of the safety of HPV vaccines.
•
Syncope can occur among adolescents who receive any vaccines, including HPV vaccine. ACIP recommends
that clinicians consider observing patients for 15 minutes after vaccination.
▶ Regardless of a safety prole that is similar to the other adolescent vaccines, parents cite safety concerns as one of the
top three reasons they do not intend to vaccinate their daughters and sons against HPV.
8
Ecacy of HPV vaccines
•
Among women who have not been previously infected with a targeted HPV type, HPV9 is estimated, via
comparisons of geometric mean titers (GMTs) vs. the previous 4-valent vaccine (HPV4), to have over 98%
ecacy in preventing cervical cancers caused by HPV types 16 or 18.
•
HPV9 also demonstrated 97% vaccine ecacy in preventing cervical, vulvar, and vaginal cancers in women
16 to 26 years of age who are naïve to HPV types 31, 33, 45, 52, or 58.
•
In males, HPV9 is estimated, via comparisons of geometric mean titers (GMTs) vs the previous 4-valent vac-
cine (HPV4), to have 89% vaccine ecacy in preventing genital warts and 75% vaccine ecacy in preventing
anal cancers caused by vaccine types 6, 11, 16, and 18.
•
Studies suggest that HPV vaccines oer long-lasting protection against HPV infection and, therefore, disease
caused by HPV infection.
▶ While HPV9 covers 90% of HPV types associated with cancer, the vaccine does not protect against all HPV types,
and so it does not replace other prevention strategies, such as regular cervical cancer screening.
What you say matters; how you say it matters even more.
Based on research conducted with parents and physicians, CDC suggests recommending the HPV vaccine
series the same way you recommend the other adolescent vaccines.
Parents may be interested in vaccinating, yet still have questions. Taking the time to listen to parents’ questions
helps you save time and give an eective response. CDC has created an excellent webinar-on-demand to assist
you in providing an eective recommendation and answering questions parents may have about HPV vaccines.
The webinar is viewable at www.cdc.gov/vaccines/ed/hpv/you-are-key-2018.html. Additionally, many other
tools on HPV vaccine are available on the CDC website at www.cdc.gov/hpv/hcp/index.html.
As a healthcare provider, we urge you to recommend HPV vaccination strongly and consistently to your patients.
Your recommendation is the number one reason why someone will get the HPV vaccine and be protected from
HPV-associated cancers and disease.
Signed:
Immunization Action Coalition
www.immunize.org/letter/recommend_hpv_vaccination.pdf
2/21
Gary LeRoy, MD, FAAFP
President, American Academy of Family Physicians
Maureen G. Phipps, MD, MPH, FACOG
Chief Executive Ocer, American College
of Obstetricians and Gynecologists
Jacqueline W. Fincher, MD, MACP
President, American College of Physicians
Deborah Wexler, MD
Executive Director, Immunization Action Coalition